L G Lum

Summary

Country: USA

Publications

  1. ncbi request reprint Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside
    L G Lum
    Roger Williams Cancer Center, Providence, RI 02908, USA
    Acta Haematol 105:130-6. 2001
  2. ncbi request reprint Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial
    L G Lum
    Cancer Immunotherapy Program, Roger Williams Cancer Center, Providence, Rhode Island, USA
    J Immunother 24:408-19. 2001
  3. ncbi request reprint Life or death of T cells with antigen-specific receptors--using T cells for cancer adoptive immunotherapy/gene therapy
    L Ren-Heidenreich
    Immunotherapy Program, Roger Williams Cancer Center, Providence, RI, USA
    Curr Gene Ther 1:253-5. 2001

Collaborators

  • L Ren-Heidenreich

Detail Information

Publications3

  1. ncbi request reprint Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside
    L G Lum
    Roger Williams Cancer Center, Providence, RI 02908, USA
    Acta Haematol 105:130-6. 2001
    ..ATC remain armed, kill tumor targets for days, and produce cytokines after binding to tumor. Arming ATC with BiAbs may prove to be effective for targeting a variety of tumors with and without high-dose chemotherapy...
  2. ncbi request reprint Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial
    L G Lum
    Cancer Immunotherapy Program, Roger Williams Cancer Center, Providence, Rhode Island, USA
    J Immunother 24:408-19. 2001
    ..The detection of cytokines in patient sera and enhanced in vitro production of cytokines by anti-CD3/anti-CD28-stimulated patient PBMCs after COACT infusions suggest that COACTs were modulating immune responses in cancer patients...
  3. ncbi request reprint Life or death of T cells with antigen-specific receptors--using T cells for cancer adoptive immunotherapy/gene therapy
    L Ren-Heidenreich
    Immunotherapy Program, Roger Williams Cancer Center, Providence, RI, USA
    Curr Gene Ther 1:253-5. 2001
    ..This review discusses the factors that affect the development of AICD or CTL proliferation, and how such factors should be considered in the design of clinical trials using ch-TCR...